MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development and commercialization of psychedelic medicines, announced...
The article MAPS Completes Second Phase 3 MDMA Trial was originally published on Microdose. MAPS PBC Completes Second Phase 3 “MAPP2” Trial of...
The results of the company’s Phase 2b trial raise concerns around safety, efficacy, and money, suggesting key questions to be addressed in Phase 3. The...
The psychedelics research company ended the quarter with less than $100K cash. The post Mydecine Continues Cash Burn through Q3 appeared first on Green...
The article Elon Talks Psychedelics: Is he Helping or Hurting the Movement? was originally published on Microdose. “Amphetamines negatively affect empathy,...
The self-dubbed “world’s leading psychedelic event" brought together a menagerie of industry titans, entrepreneurs, and psychedelic luminaries, showcasing...
If you are reading this, you probably turn to a doctor with a reputable medical degree when you get sick. Most people, however, do not have...
The article Alberta’s Psychedelic Therapy Laws: What Are the Implications? was originally published on Microdose. In diverse cities, provinces and states...
The article Atai Reports Q3 Financials and Business Update was originally published on Microdose. atai Life Sciences has the biggest product portfolio...
The non-profit trade association received a high level of interest from multiple branches of government The post PsyCan aims to be ‘go-to’ psychedelics...